The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses

Cancer Gene Therapy

Volumn 19, Issue 1, 2012, Pages 58-68

  Durupt, F ^a,b   Koppers Lalic, D ^b,c   Balme, B ^a   Budel, L ^b   Terrier, O ^a   Lina, B ^a   Thomas, L ^a   Hoeben, R C ^b   Rosa Calatrava, M ^a  

^a UNIVERSITÉ LYON 1   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Cancer Center   (Netherlands)

Author keywords

adenovirus; chorioallantoic membrane; melanoma; oncolytic viruses; the 3Rs; viral fusion glycoprotein

Indexed keywords

ADENOVIRUS VECTOR; HYBRID PROTEIN; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL FUSION; CHICKEN; CHORIOALLANTOIS; COLORECTAL CARCINOMA; DRUG SCREENING; GENETIC CODE; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SIMIAN PARAINFLUENZA VIRUS 5; SYNCYTIOTROPHOBLAST; VIRUS REPLICATION; ZYGOTE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CHICKENS; CHORIOALLANTOIC MEMBRANE; COLORECTAL NEOPLASMS; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

ADENOVIRIDAE; ANIMALIA; MUS; PARAINFLUENZA VIRUS;

EID: 83555174427     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.68     Document Type: Article

References (37)

1. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001; 61: 6592-6600. (Pubitemid 32783269)
2. Kuppen PJ, van der Eb MM, Jonges LE, Hagenaars M, Hokland ME, Nannmark U et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem Cell Biol 2001; 115: 67-72. (Pubitemid 32202055)
3. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 2001; 12: 1323-1332. (Pubitemid 32681846)
4. Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003; 14: 425-433. (Pubitemid 36403535)
5. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44. (Pubitemid 27075341)
6. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumorbearing mice. Cancer Res 2007; 67: 4399-4407. (Pubitemid 46815089)
7. Kim J-H, Lee Y-S, Kim H, Huang J-H, Yoon AR, Yun C-O. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482-1493. (Pubitemid 44605593)
8. Gros A, Mart?́nez-Quintanilla J, Puig C, Guedan S, Mollev?́ DG, Alemany R et al. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 2008; 68: 8928-8937.
9. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006; 10: 588-612. (Pubitemid 44874273)
10. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005; 65: 5292-5300. (Pubitemid 40827341)
11. Ong HT, Trejo TR, Pham LD, Oberg AL, Russell SJ, Peng KW. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol Ther 2009; 17: 1012-1021.
12. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353-362. (Pubitemid 28376079)
13. Lugassy C, Kleinman HK, Engbring JA, Welch DR, Harms JF, Rufner R et al. Pericyte-like location of GFP-tagged melanoma cells: ex vivo and in vivo studies of extravascular migratory metastasis. Am J Pathol 2004; 164: 1191-1198. (Pubitemid 38387786)
14. Lugassy C, Vernon SE, Busam K, Engbring JA, Welch DR, Poulos EG et al. Angiotropism of human melanoma: studies involving in transit and other cutaneous metastases and the chicken chorioallantoic membrane: implications for extravascular melanoma invasion and metastasis. Am J Dermatopathol 2006; 28: 187-193. (Pubitemid 44270851)
15. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res 2002; 62: 7083-7092. (Pubitemid 35424104)
16. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005; 102: 1643-1648. (Pubitemid 40209221)
17. Taizi M, Deutsch VR, Leitner A, Ohana A, Goldstein RS. A novel and rapid in vivo system for testing therapeutics on human leukemias. Exp Hematol 2006; 34: 1698-1708. (Pubitemid 44838998)
18. Kobayashi T, Koshida K, Endo Y, Imao T, Uchibayashi T, Sasaki T et al. A chick embryo model for metastatic human prostate cancer. Eur Urol 1998; 34: 154-160. (Pubitemid 28398467)
19. Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Therapy 2008; 15: 1240-1245.
20. Li H, Haviv YS, Derdeyn CA, Lam J, Coolidge C, Hunter E et al. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum Gene Ther 2001; 12: 2155-2165. (Pubitemid 34075181)
21. Terrier O, Durupt F, Cartet G, Thomas L, Lina B, Rosa-Calatrava M. Engineering of a parainfluenza virus type 5 fusion protein (PIV-5 F): development of an autonomous and hyperfusogenic protein by a combinational mutagenesis approach. Virus Res 2009; 146: 115-124.
22. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509. (Pubitemid 26339054)
23. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9: 1909-1917. (Pubitemid 28439096)
24. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148: 3-15.
25. Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models? Eur J Cancer 2009; 45: 2768-2781.
26. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007; 2: 247-250. (Pubitemid 47040037)
27. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007; 85: 133-148. (Pubitemid 47629395)
28. Lam JT, Hemminki A, Kanerva A, Lee KB, Blackwell JL, Desmond R et al. A three-dimensional assay for measurement of viral-induced oncolysis. Cancer Gene Ther 2007; 14: 421-430. (Pubitemid 46425786)
29. Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D et al. Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS One 2009; 4: e5119.
30. Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S et al. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Therapy 2003; 10: 1663-1671. (Pubitemid 37069494)
31. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492-1497. (Pubitemid 30183412)
32. Lin EH, Salon C, Brambilla E, Lavillette D, Szecsi J, Cosset FL et al. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer. Cancer Gene Ther 2010; 17: 256-265.
33. Lamfers MLM, Gianni D, Tung C-H, Idema S, Schagen FHE, Carette JE et al. Tissue inhibitor of metalloproteinase-expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res 2005; 65: 9398-9405 (Pubitemid 41508008)
34. Fang L, Pu Y-Y, Hu X-C, Sun L-J, Luo H-M, Pan S-K et al. Antiangiogenesis gene armed tumor-targeting adenovirus yields multiple antitumor activities in human HCC xenografts in nude mice. Hepatol Res 2010; 40: 216-228.
35. He X-P, Su C-Q, Wang X-H, Pan X, Tu Z-X, Gong Y-F et al. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett 2009; 285: 89-98.
36. Yoo JY, Kim J-H, Kwon Y-G, Kim E-C, Kim NK, Choi HJ et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther: J Am Soc Gene Ther 2007; 15: 295-302. (Pubitemid 46111879)
37. Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B et al. Suppression of tumor growth by oncolytic adenovirusmediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther: J Am Soc Gene Ther 2005; 11: 553-562. (Pubitemid 40353113)